Antisense oligonucleotides - The way forward

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Antisense oligonucleotides provide attractive possibilities for developing a new class of drugs and the design principle involves straightforward base-pairing rules. The approach has already been useful in many functional genomics efforts and there has also been recent clinical success. With this progress in place, it now is appropriate to thoroughly address design uncertainties and unforeseen effects that have emerged. The key objective has long been, and remains to be, the identification of novel oligonucleotide analogs providing the possibility of achieving high in vivo efficacy in the absence of significant toxicity; such compounds are not at hand today but certain advances have been made in recent years. There is also a need for more expertise in target site selection and for improving delivery and/or bioavailability properties. Immediately achievable goals in the field implicate use of improved in vitro and in vivo assays and, importantly, a set of standard controls, uniform between laboratories, such that results can be compared in a rational manner. In turn, this should lead to the emergence of antisense agents that are useful for a wide range of research and therapeutic applications.

Original languageEnglish
Pages (from-to)142-146
Number of pages5
JournalCurrent Opinion in Drug Discovery and Development
Volume2
Issue number2
StatePublished - Apr 14 1999
Externally publishedYes

Fingerprint

Therapeutic Human Experimentation
Antisense Oligonucleotides
Drug Design
Genomics
Oligonucleotides
Base Pairing
Biological Availability
Uncertainty
Hand
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Antisense oligonucleotides - The way forward. / Wahlestedt, Claes R; Good, Liam.

In: Current Opinion in Drug Discovery and Development, Vol. 2, No. 2, 14.04.1999, p. 142-146.

Research output: Contribution to journalArticle

@article{4d765a6ddf92416ca547378238037e0f,
title = "Antisense oligonucleotides - The way forward",
abstract = "Antisense oligonucleotides provide attractive possibilities for developing a new class of drugs and the design principle involves straightforward base-pairing rules. The approach has already been useful in many functional genomics efforts and there has also been recent clinical success. With this progress in place, it now is appropriate to thoroughly address design uncertainties and unforeseen effects that have emerged. The key objective has long been, and remains to be, the identification of novel oligonucleotide analogs providing the possibility of achieving high in vivo efficacy in the absence of significant toxicity; such compounds are not at hand today but certain advances have been made in recent years. There is also a need for more expertise in target site selection and for improving delivery and/or bioavailability properties. Immediately achievable goals in the field implicate use of improved in vitro and in vivo assays and, importantly, a set of standard controls, uniform between laboratories, such that results can be compared in a rational manner. In turn, this should lead to the emergence of antisense agents that are useful for a wide range of research and therapeutic applications.",
author = "Wahlestedt, {Claes R} and Liam Good",
year = "1999",
month = "4",
day = "14",
language = "English",
volume = "2",
pages = "142--146",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Antisense oligonucleotides - The way forward

AU - Wahlestedt, Claes R

AU - Good, Liam

PY - 1999/4/14

Y1 - 1999/4/14

N2 - Antisense oligonucleotides provide attractive possibilities for developing a new class of drugs and the design principle involves straightforward base-pairing rules. The approach has already been useful in many functional genomics efforts and there has also been recent clinical success. With this progress in place, it now is appropriate to thoroughly address design uncertainties and unforeseen effects that have emerged. The key objective has long been, and remains to be, the identification of novel oligonucleotide analogs providing the possibility of achieving high in vivo efficacy in the absence of significant toxicity; such compounds are not at hand today but certain advances have been made in recent years. There is also a need for more expertise in target site selection and for improving delivery and/or bioavailability properties. Immediately achievable goals in the field implicate use of improved in vitro and in vivo assays and, importantly, a set of standard controls, uniform between laboratories, such that results can be compared in a rational manner. In turn, this should lead to the emergence of antisense agents that are useful for a wide range of research and therapeutic applications.

AB - Antisense oligonucleotides provide attractive possibilities for developing a new class of drugs and the design principle involves straightforward base-pairing rules. The approach has already been useful in many functional genomics efforts and there has also been recent clinical success. With this progress in place, it now is appropriate to thoroughly address design uncertainties and unforeseen effects that have emerged. The key objective has long been, and remains to be, the identification of novel oligonucleotide analogs providing the possibility of achieving high in vivo efficacy in the absence of significant toxicity; such compounds are not at hand today but certain advances have been made in recent years. There is also a need for more expertise in target site selection and for improving delivery and/or bioavailability properties. Immediately achievable goals in the field implicate use of improved in vitro and in vivo assays and, importantly, a set of standard controls, uniform between laboratories, such that results can be compared in a rational manner. In turn, this should lead to the emergence of antisense agents that are useful for a wide range of research and therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=0032945649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032945649&partnerID=8YFLogxK

M3 - Article

C2 - 19649940

AN - SCOPUS:0032945649

VL - 2

SP - 142

EP - 146

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 2

ER -